**Name of journal: *World Journal of Hepatology***

**ESPS Manuscript NO: 24991**

**Manuscript type: Topic highlight**

**2016 Hepatocellular Carcinoma: Global view**

**Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments**

Adhoute X *et al*. HCC treatment: classifications and scores complementarity

**Xavier Adhoute, Guillaume Penaranda, Jean Luc Raoul, Patrice Le Treut, Emilie Bollon, Jean Hardwigsen, Paul Castellani, Hervé Perrier, Marc Bourlière**

**Xavier Adhoute, Paul Castellani, Hervé Perrier, Marc Bourlière,** Department of Hepato-Gastroenterology, Hôpital Saint-Joseph, 13008 Marseille, France

**Guillaume Penaranda,** AlphaBio Laboratory, 13008 Marseille, France

**Jean Luc Raoul,** Department of Hepato-Gastroenterology and Digestive Oncology, Institut Paoli-Calmette, 13008 Marseille, France

**Patrice Le Treut, Emilie Bollon, Jean Hardwigsen,** Department of Hepatobiliary Surgery, Centre Hospitalo-Universitaire Timone, 13008 Marseille, France

**Author contributions:** Adhoute X, Le Treut P, Bollon E, Hardwigsen J, Castellani P, Perrier H and Bourlière M collected the data; Penaranda G proceeded to statistical analysis; Adhoute X, Penaranda G, Raoul JL and Bourlière M wrote the manuscript.

**Conflict-of-interest statement:** Raoul JL, Board member (Bayer, BMS, Daichi). Bourliere M, Board member (Merck-Schering Plough, Gilead, Janssen, Vertex, Boehringer-Ingelheim, BMS, Roche, Abbvie, GSK); Speaker (Merck-Schering Plough – Gilead, Janssen, Vertex, Boehringer-Ingelheim, BMS, Roche, Abbvie, Novartis, GSK). Adhoute X, Penaranda G, Bollon E, Castellani P, Perrier H, Hardwigsen J and Le Treut P declare that they have no conflict of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:**Invited manuscript

**Correspondence to:** **Dr. xavier Adhoute,** Department of Hepato-Gastroenterology, Hôpital Saint-Joseph, 26 Bd de Louvain, 13008 Marseille, France. adhoute.xavier@neuf.fr

**Telephone:** +33-49-1807065

**Fax:** +33-49-1806912

**Received:** February 17, 2016

**Peer-review started:** February 19, 2016

**First decision:** April 5, 2016

**Revised:** April 24, 2016

**Accepted:** May 17, 2016

**Article in press:**

**Published online:**

**Abstract**

Therapeutic management of hepatocellular carcinoma (HCC) is quite complex owing to the underlying cirrhosis and portal vein hypertension. Different scores or classification systems based on liver function and tumoral stages have been published in the recent years. If none of them is currently ‘universally’ recognized, the Barcelona Clinic Liver Cancer (BCLC) staging system has become the reference classification system in Western countries. Based on a robust treatment algorithm associated with stage stratification, it relies on a high level of evidence. However, BCLC stage B and C HCC include a broad spectrum of tumors but are only matched with a single therapeutic option. Some experts have thus suggested to extend the indications for surgery or for transarterial chemoembolization. In clinical practice, many patients are already treated beyond the scope of recommendations. Additional alternative prognostic scores that could be applied to any therapeutic modality have been recently proposed. They could represent complementary tools to the BCLC staging system and improve the stratification of HCC patients enrolled in clinical trials, as illustrated by the NIACE score. Prospective studies are needed to compare these scores and refine their role in the decision making process.

**Key words:** Hepatocellular carcinoma; scoring system; Barcelona Clinic Liver Cancer staging system; transarterial chemoembolization; NIACE

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Different scores or classification systems have been proposed to refine hepatocellular carcinoma (HCC) prognosis and better guide medical treatment. The Barcelona Clinic Liver Cancer (BCLC) system has become the reference classification in Western countries. Its treatment algorithm is based on randomized studies, but only offers one recommendation for BCLC stages B and C, whereas they include a broad spectrum of tumors. In clinical practice, many patients are treated out of the scope of these recommendations. In this context, alternative scores or classifications, which have been opposed for a long time, could be complementary tools for the benefit of the treatment.

Adhoute X, Penaranda G, Raoul JL, Le Treut P, Bollon E, Hardwigsen J, Castellani P, Perrier H, Bourlière M. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. *World J Hepatol* 2016; In press

**Introduction**

Most hepatocellular carcinomas (HCC) develop upon chronic diseases of the liver, mainly B or C viral hepatitis. HCC is a frequent and serious cancer, often diagnosed at an inoperable stage[1]. It is singular as its prognosis not only relies on the tumor characteristics but also on the underlying liver disease, frequently at a cirrhotic stage. The TNM classification of solid tumors failed to impose itself as the reference system for such a dual pathology, despite its recognized prognostic value even for non-operated tumors[2]. In order to refine the prognosis and provide better medical care, different scores or classifications originating from Asian or Western countries have been published recently. Most of them use regression models based on the prognostic variables of the studied populations. If they all share common parameters including liver function, tumor characteristics, age-related clinical consequences, comorbidities or cirrhosis (Figure 1), there is no universally recognized score or classification to date.

In the first part, we will focus on the main scores and classification systems published in the recent years, following a chronological order and revealing the differences between Western and Asian countries, the corresponding affected populations, treatment modalities and recommendations being distinct. The second part highlights the complementarity between the two systems in the decision making process (excluding graft), as successively exemplified by the sorafenib, the transarterial chemoembolization (TACE), the radiofrequency ablation (RFA) and the surgical resection treatments.

**HCC prognosis: Scores or classifications?**

The OKUDA score, published in the eighties, was the first to combine tumor-associated parameters (more *vs* less than 50% of invaded parenchyma) and liver function (ascites, albumin, bilirubin) (Tables 1 and 2). It classifies patients into three stages [lowly (I), moderately (II) or highly advanced (III)] with different outcomes, depending on their number of positive variables (0 *vs* 1-2 *vs* 3-4, respectively). This score was initially validated on a population of 850 patients, either non-treated or treated according to the modalities applicable at that time (surgery, intra-arterial or systemic chemotherapy, arterial embolization)[3]. Although approximative and hardly differentiating the less advanced patients (*e.g.*, the median survival of stage I patients was 11.5 months independently of the treatment *vs* 25.6 mo when operated), this score has been widely used.

Published in the late nineties, the Italian Cancer of the Liver Italian Program (CLIP) score was calculated from the prognostic values of 435 patients originating from 16 centers (Tables 1 and 2)[4]. It includes other tumor-linked parameters such as portal vein thrombosis or alpha-fetoprotein (AFP) serum levels and better estimates the liver function using the Child-Pugh score. Easy to calculate (4 variables to add), it is well correlated with survival (CLIP 0, 1, 2, 3, 4, 5-6: 42.5 *vs* 32 *vs* 16.5 *vs* 4.5 *vs* 2.5 *vs* 1.0 mo). The CLIP score was first assessed on a prospective cohort[5,6] and subsequently validated on Asian cohorts[7]. Still recently ranked first for its ability to predict survival[8], it was criticized for its lack of treatment offer, approximation in tumor morphology and extension, for the absence of clinical status consideration and its inability to classify intermediate stages. Another issue is that studies evaluating the CLIP system mainly included patients with scores only ranging from 0 to 2[7-9].

French speaking teams have created the GRETCH score in 1999. Quite similar to the CLIP, it further includes the patients’ overall condition but lacks tumor morphology information[10]. Also determined from a multivariate analysis including 761 patients (mainly non-treated) from 24 centers, it identifies 3 different groups (A: 0, B: 1 to 5 and C: 6 to 11 points) with distinct prognosis (overall survival after a year: A (72%), B (34%), C (7%), respectively). Less evaluated than the CLIP, it faces the same limitations.

The BCLC classification was published at the same time[11]. Differently built as it is not based on a regression model but results from the combination of different studies, it distinguishes 4 different stages [A: (very) early, B: intermediate, C: advanced, D: terminal] with different prognosis, according to the liver function, the extent of the tumor and its consequences (Figure 2). As opposed to the previous scores, the early stages are well defined according to the number and size of nodules, the associated comorbidities and the portal vein pressure. The BCLC staging system was assessed on Western and Asian cohorts[12,13] and demonstrated a better ability to predict survival than most other scores[9,14]. This classification has imposed itself from its practical aspect and for being the only one linked to a treatment algorithm relying on a high level of evidence for each modality. Endorsed by both the EASL[15] and the AASLD[16], it has become the reference classification in Western countries and is being used in day-to-day practice and clinical trials.

However, BCLC is not the reference classification in Asia, notably as HCC treatment modalities differ according to the countries (*e.g.* external radiotherapy, intra-arterial and systemic chemotherapy or TACE being indicated for advanced HCC despite a low level of evidence[17]). Such recommendations are based on studies but, as opposed to the BCLC, also rely on personal experience, experts advice and consensus conferences. Alternative scores or classifications have thus been proposed.

The Japan Integrated Staging (JIS) score was published in 2003 (Table 3)[18]. Also easy to calculate, it associates the Child-Pugh score and the Japanese TNM, which is based on three parameters (vascular invasion, unique vs. multiple nodules, diameter ≤ *vs* > 20 mm) determined from a population of 13772 operated patients. It defines six groups with different prognosis (excluding JIS 4-5). This score has demonstrated a better ability to predict survival than the CLIP and was further improved a few years later with the modified-JIS (m-JIS)[19], in which the encephalopathy item is replaced by the indocyanine green clearance, due to an early HCC screening in Japan and a preferred surgical orientation. In 2008, the JIS score became the biomarker combined JIS (bm-JIS) with the inclusion of three HCC serum markers [AFP, AFP–L3 (AFP-Lens culinaris agglutinin-reactive) and DCP (des-gamma-carboxy prothrombin)], which allowed better survival predictions (Table 3)[20]. However, two of those markers are not frequently used in Western countries where HCC is also often being diagnosed at more advanced stages. Thus, this score, without treatment guidelines, has not been evaluated on patients from Western countries.

The Taipei Integrated Scoring system (TIS) was published in 2010[21] arised from the lack of a reference classification and the opposite results from studies regarding the performance of classification systems. TIS is a point scoring system combining AFP levels (< 400 *vs* > 400 ng/ml: 0 *vs* 1 point), Child-Pugh score (A, B and C : 0, 1 and 2 points, respectively) and the sum of the volume of each tumor (Total tumor volume or TTV), calculated from the following formulae: [(4/3) × 3.14 × (radius of tumor in cm)(3)], and which defines 4 different groups (< 50 cm3, 50-250 cm3, 250-500 cm3, > 500 cm3: 0, 1, 2 or 3 points, respectively). From a cohort of 2030 patients, mainly with viral hepatitis (VHB 51%, VHC 27%), the score identified six distinct prognostic groups, with a score evolution inversely correlated to survival. The predictive ability of the TIS score was better than the JIS and the BCLC for the whole cohort, independently of the treatment modality (curative or palliative), but not as good as the CLIP for the 936 patients treated with curative intent. Vascular invasion that was observed in 36.7% of the patients is taken into account in the CLIP but not in the TIS, which probably participates in this discrepancy. Again, this score appears promising, but lacks a linkage to any treatment decision choice and has not been validated on any Western country patient.

In 2011, an Asian experts meeting has suggested to adopt a common classification and common recommendations. TACE was then proposed for HCC with limited vascular invasion, despite a low level of evidence (Figure 3)[17]. The competing Hong Kong Liver Cancer (HKLC) classification, which is close to the BCLC system, was published in 2014[22]. Built from a population of 3856 patients (median age: 58 years old), mainly affected by viral hepatitis B, with Child-Pugh A scores (73%), it identifies five groups and nine sub-groups to further refine the prognosis (Figure 4). The associated treatment algorithm recommended surgery at more advanced stages and subsequently increased survival according to the authors. However, its prognostic value was comparable to the BCLC system for a European cohort of HCC linked to viral hepatitis C or alcohol, the IIa/IIb, IIIb/IVa, IVb/Vb subgroups presenting similar survival[23], which limits the impact of such a stratification within this population. A prospective study is currently on-going to further evaluate this score.

Overall, the BCLC classification has become the reference in Western countries and has replaced the other prognostic scores. Limitations have however been highlighted since several years. The intermediate BCLC B stage, which gathers multifocal tumors lacking vascular invasion and excludes unique and large HCC, now part of the BCLC A group in newer version of the BCLC classification[24], remains heterogeneous[25]. Thus, a diffuse multinodular HCC or four nodules of one centimeter in size within the same lobe are categorized within the same BCLC B group, and only a single therapeutic option is offered (i.e. chemoembolization). Advanced (BCLC C) stages encompass a broad spectrum of tumors, including cancers with or without symptoms, metastatic or locally advanced diseases, eventually associated with portal thrombosis, nodular or infiltrating tumors, uni- or multi-nodular tumors, associated with Child-Pugh A or B grade, which are, again, only associated with a single treatment (sorafenib)[24]. It has thus been suggested to extend the indication for surgery[26-28] or chemoembolization to some advanced stages[29,30]. Stage C HCC were defined using a population limited to 102 patients[31]. Furthermore, comparative studies have shown lower prognostic ability for the BCLC than the CLIP score regarding advanced HCC[32-34], and several studies have suggested a possible stratification for the BCLC C HCC[35-37]. For example, Yau *et al*[36] have proposed a new score called Advanced Liver Cancer Prognostic System (ALCPS), separating 3 groups according to their survival after 3 mo, and aiming at improving patients selection before their enrollment into clinical trials (Table 4). However, the ALCPS score is too complex for daily clinical practice as it includes eleven variables with different coefficients, as is the Chinese University Prognostic Index (CUPI) score[37].

Conversely, the recently published NIACE score[38] (Table 5) was determined from a population of advanced HCC and validated using an external Asian cohort, independently of the BCLC stage[39]. Easy to calculate and well correlated to survival, it distinguishes 2 subgroups with different prognosis within BCLC stage C patients. Advanced HCC are classified according to their morphology as infiltrating or diffuse (hardly delimited lesion, with a heterogeneous enhancement, more easily characterized using MRI[40] and frequently associated with portal vein thrombosis[41] or bile duct invasion), as opposed to the nodular HCC meeting the EASL/AASLD diagnosis criteria[42]. It also considers the AFP level (± 200 ng/ml), whose prognostic value has been demonstrated independently of the stage of the disease[4,10,43]; those two last criteria missing from the BCLC system.

The predictive value of the NIACE score has been compared to those of the CLIP score and both the BCLC and HKLC classifications using a French multicenter HCC cohort of 1102 patients, of 68 (60-74) years of age, mostly with cirrhosis (81%), often linked to alcohol (41%) or hepatitis C (28%) or B (6%) viruses; most of the patients with Child-Pugh A and BCLC C scores, and treated according to the following modalities: curative treatment in 22% of the cases (surgical resection or RFA), palliative treatment in 66% of the cases (TACE, Sorafenib) and supportive care in 12% of the cases[44]. Each scoring system identified different prognosis subgroups (*p* < 0.0001), with scores and classifications correlated with survival. The NIACE score showed the best homogeneity (LR *χ²* = 532.0369, *p* < 0.0001), the best discriminative ability (LT *χ²* = 91.6906, *p* < 0.0001), the lowest Akaike information criterion (AIC 10648.198) and the highest C-index (C-index 0.718 [0.688-0.748]) (Table 6). Using a threshold value of 1 or 2.5, the NIACE score identified 2 distinct prognosis groups within the CLIP 0, 1, 2 and 3 groups (*p* < 0.0001). As opposed to the HKLC, when applied to the various HKLC groups with similar survival (*i.e.* IIa/IIb, IIIb/IVa, IVb/Vb), the NIACE score highlighted 2 different prognosis subgroups using a threshold value of 3 (*p* < 0.0001). The same results were obtained when investigating the HKLC I group using a threshold value of 1 (*p* < 0.0001)[45].

In conclusion, the use of additional prognostic scores improves the stratification of HCC selected according to the BCLC system.

**HCC classification and prognostic scores: a useful complementarity for treatment choice**

***Prognostic scores benefit in HCC treatment: before Sorafenib***

Sorafenib is recommended for BCLC stage C HCC[46,47] and is also a possible alternative for some BCLC stage B HCC being either progressive or confronted with chemoembolization contraindication[48]. The NIACE score allows to further stratify the BCLC stage C patients treated with Sorafenib (Figure 5), by separating two distinct groups with different survival using a threshold value of 3[38]. The survival of patients with a NIACE score > 3 is limited to around 5.0 mo, despite a median treatment duration of 2 mo. Thus, this population does not seem to really benefit from the treatment and the NIACE score could be helpful in the treatment choice process or even earlier, to better classify patients before their enrollment into clinical trials.

***Prognostic scores benefit in HCC treatment: before chemoembolization***

As chemoembolization is mainly recommended for intermediate BCLC stage B HCC[24], the usefulness of any additional prognostic score for such cases appears limited to some experts. However, if TACE remains the main treatment modality in most countries confronted with this disease[1], it is controversial. Its validation relies on two randomized studies with limited patients groups, mainly including intermediate and advanced HCC, and each offering a different treatment option[49,50]. Metadata analyses show contradictory results[51,52] and, despite the improvement of the selection criteria, the radiological response (according to the EASL or the mRECIST criteria)[53,54], the existing contraindications[55] or treatment termination criteria[56], there is still no consensus regarding the treatment strategy (on-demand or sequential), the number of treatments before reassessment[57], the overall aim (stability or response)[55,56] or concerning the TACE mode (using conventional techniques or calibrated drug-eluting beads). An additional score could thus facilitate the treatment strategy choice.

***Before the first treatment***

Several scores have been proposed recently to improve candidate patient selection (Table 7), as TACE is a potentially toxic treatment, with limited survival benefit. Among these pre-therapeutic scores, the HAP (Hepatoma Arterial-embolisation Prognostic) and the STATE (Selection for TrAnsarterial chemoembolisation TrEatment) scores were determined from the prognostic variables of around a hundred of BCLC stage A, B (HAP, STATE) or even C (HAP) patients treated by TACE[58,59]. The NIACE score was also evaluated on two cohorts adding up 321 BCLC A, B or sometimes C (with distal portal vein thrombosis) patients treated by TACE. Using a threshold value of 3, the NIACE score identified two groups presenting a significantly different survival (NIACE ≤ 3:27 mo [24-31] *vs* NIACE > 3:7 mo [6-10], *p* < 0.0001), even without any stage C patients (Figure 6)[60]. It also separated two subgroups with distinct prognosis from an Asian cohort of patients treated by TACE[39], as opposed to the HAP score which failed to prove its ability to select all the “good” candidates for TACE from a multicenter European cohort (with similar survival between the subgroups)[61]. Such a result could be anticipated as the same rating (1 point) is attributed to each variable and only HCC > 70 mm are taken into account, whereas the efficiency of the TACE treatment relies on the size (generally < 50 mm) and the number of nodules. The more recent STATE score, which mainly focuses on multinodular (BCLC B) HCC, still needs to be evaluated. The list presented here is not exhaustive and some relatively new scores now include indocyanine green clearance to better evaluate the liver function before TACE[29], but often at the expense of simplicity, which should remain a priority.

The continuation of a TACE treatment is determined by the radiological response (which is correlated to survival after TACE[53]), a decrease in AFP levels and the impact of the treatment on the liver function.

**After the first TACE:** Two scores easy to calculate were proposed to improve the selection of patients before repeating the treatment: the ART (Assessment for Retreatment with TACE) and the ABCR scores, both defined using regression models[38,62]. The ART score associates its higher coefficient with a possible increase in ASAT levels (4 points), the lower being associated with the radiological response (1 point). It is recommended not to repeat the treatment in case of a score worsening ≥ 2.5 points (Table 8). Conversely, the ABCR system assigns a higher coefficient to the radiological response (-3 points), which is correlated to survival after TACE and to the initial stage of the disease (BCLC A/B/C: 0/2/3 points). The associated threshold value is a score worsening > 2 points. Both scores are usable after the second treatment. From a European multicenter cohort, the ART score calculated before the second or the third TACE failed to orientate the treatment option for all the patients[38,61]. If, unlike the ABCR, it did discriminate two different prognosis subgroups, the evolution of the ART score was not correlated with survival. As expected, patients with an ART score of 1 (*i.e.* no radiological response) presented a lower survival than the ART 4 (ASAT levels increase > 25%) patients. Among the ABCR score limitations stands the possible absence of radiological response after the first TACE, which affects almost 25% of the “late responders”, depending on the series[63]. The score being contributory after the second TACE, it is recommended to repeat the treatment in the absence of obvious progression and in case of worsening hepatic function.

The prognostic ability of the ABCR score was higher than the HAP and ART systems on both Western[64] and Asian cohorts[65].

Overall, these pre-chemoembolization scores are not able to embrace all the patients or situations and cannot replace a multidisciplinary meeting. However, owing to the high number of patients treated following this modality, the heterogeneity of HCC and day-to-day practices, such scores could help in the therapy decision making process (Figure 7).

***prognostic scores benefit in hcc treatment: before surgical resection or radiofrequency***

Surgical resection and radiofrequency ablation are curative treatments for HCC. In such cases, a score is not meant to exclude patients from the treatment when they meet the Barcelona criteria, early (BCLC A) stages being more homogeneous (single nodule or 3 nodules ≤ 3 cm), but to further evaluate their prognosis (overall survival and recurrence), in the prospect of a possible complementary treatment. This is illustrated by the nomogram recently proposed by Liu et al, which orientates stage A HCC towards surgery or RFA according to the risk of recurrence[66] (Figure 8). However, some experts have proposed to extend the indication for surgery beyond the Barcelona criteria to some intermediate or advanced HCC, which are more heterogeneous[27]. Despite some interesting results, only a proper randomized comparative study could address this question using a prognostic score to improve patient classification.

The NIACE score was tested on two French cohorts, both including around one hundred BCLC A/B and even C (single nodule with segmental portal vein thrombosis or above) HCC patients treated by surgery, thus beyond the scope of the BCLC recommendation, but in agreement with day-to-day practice. Using the more stringent threshold value of 1, it identified two different prognosis groups regarding the median overall survival (NIACE ≤ 1:61 mo [36-81] *vs* NIACE > 1:18 mo [9-73], *p* = 0.0005) and the mean time to progression (NIACE ≤ 1, 26.9 ± 16.3 mo *vs* NIACE > 1, 9.2 ± 9.7 mo, *p* < 0.0001)[67]. The score evolution was inversely correlated to survival (Figure 9). Similar results were observed using an Asian cohort comprising around one hundred BCLC A/B/C HCC patients treated by surgery[39].

When tested on a group of BCLC A HCC patients treated by surgery, selected from a French multicenter cohort, the NIACE score also highlighted two subgroups with distinct prognosis (median OS NIACE ≤ 1:80 [58-81] mo *vs* NIACE > 1:39 [28-58] mo, *p* = 0.0011), notably among patients with a single tumor exceeding 50 mm in the longest axis (median OS NIACE ≤ 1:80 [58-80] mo *vs* NIACE > 1:35 [18-58] mo, *p* = 0.0024)[44].

These results should be further confirmed by a prospective study but, again, an additional prognostic score could provide complementary information to the BCLC system.

**Conclusion**

HCC prognostic scores or classifications competed against each other until recently. A straightforward distribution and the corresponding treatment guide have allowed the BCLC classification to impose itself as the reference system in Western countries, and the HKLC system might do as well in Asian countries. However, owing to the heterogeneity of HCC, patients and daily practices, alternative scores such as NIACE, which includes different prognostic variables, could provide complementary tools to clinicians to better anticipate the disease evolution and optimize the stratification of patients within clinical trial or in the treatment decision making itself.

**References**

1 **Park JW**, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, Sherman M. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. *Liver Int* 2015; **35**: 2155-2166 [PMID: 25752327 DOI: 10.1111/liv.12818]

2 **Kee KM**, Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC, Chen TY, Lin CY, Lu SN. Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan. *Int J Cancer* 2007; **120**: 2650-2655 [PMID: 17304512 DOI: 10.1002/ijc.22616]

3 **Okuda K**, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. *Cancer* 1985; **56**: 918-928 [PMID: 2990661]

4 A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. *Hepatology* 1998; **28**: 751-755 [PMID: 9731568 DOI: 10.1002/hep.510280322]

5 Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. *Hepatology* 2000; **31**: 840-845 [PMID: 10733537 DOI: 10.1053/he.2000.5628]

6 **Llovet JM**, Bruix J. Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. *Hepatology* 2000; **32**: 679-680 [PMID: 10991637 DOI: 10.1053/jhep.2000.16475]

7 **Ueno S**, Tanabe G, Sako K, Hiwaki T, Hokotate H, Fukukura Y, Baba Y, Imamura Y, Aikou T. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. *Hepatology* 2001; **34**: 529-534 [PMID: 11526539 DOI: 10.1053/jhep.2001.27219]

8 **Liu PH**, Hsu CY, Hsia CY, Lee YH, Su CW, Huang YH, Lee FY, Lin HC, Huo TI. Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. *J Hepatol* 2016; **64**: 601-608 [PMID: 26551516 DOI: 10.1016/j.jhep.2015.10.029]

9 **Cillo U**, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, Neri D, Boccagni P, Srsen N, D'Amico F, Ciarleglio FA, Bridda A, D'Amico DF. Prospective validation of the Barcelona Clinic Liver Cancer staging system. *J Hepatol* 2006; **44**: 723-731 [PMID: 16488051 DOI: 10.1016/j.jhep.2005.12.015]

10 **Chevret S**, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. *J Hepatol* 1999; **31**: 133-141 [PMID: 10424293]

11 **Llovet JM**, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. *Semin Liver Dis* 1999; **19**: 329-338 [PMID: 10518312 DOI: 10.1055/s-2007-1007122]

12 **Marrero JA**, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, Lok AS. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. *Hepatology* 2005; **41**: 707-716 [PMID: 15795889 DOI: 10.1002/hep.20636]

13 **Wang JH**, Changchien CS, Hu TH, Lee CM, Kee KM, Lin CY, Chen CL, Chen TY, Huang YJ, Lu SN. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. *Eur J Cancer* 2008; **44**: 1000-1006 [PMID: 18337087 DOI: 10.1016/j.ejca.2008.02.018]

14 **Guglielmi A**, Ruzzenente A, Pachera S, Valdegamberi A, Sandri M, D'Onofrio M, Iacono C. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. *Am J Gastroenterol* 2008; **103**: 597-604 [PMID: 17970836 DOI: 10.1111/j.1572-0241.2007.01604.x]

15 **Bruix J**, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. *J Hepatol* 2001; **35**: 421-430 [PMID: 11592607]

16 **Bruix J**, Sherman M; [Practice Guidelines Committee, American Association for the Study of Liver Diseases](http://www.ncbi.nlm.nih.gov/pubmed/?term=Practice%20Guidelines%20Committee%2C%20American%20Association%20for%20the%20Study%20of%20Liver%20Diseases%5BCorporate%20Author%5D). Management of hepatocellular carcinoma. *Hepatology* 2005; **42**: 1208-1236 [PMID: 16250051 DOI: 10.1002/hep.20933]

17 **Han KH**, Kudo M, Ye SL, Choi JY, Poon RT, Seong J, Park JW, Ichida T, Chung JW, Chow P, Cheng AL. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. *Oncology* 2011; **81 Suppl 1**: 158-164 [PMID: 22212951 DOI: 10.1159/000333280]

18 **Kudo M**, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). *J Gastroenterol* 2003; **38**: 207-215 [PMID: 12673442 DOI: 10.1007/s005350300038]

19 **Ikai I**, Takayasu K, Omata M, Okita K, Nakanuma Y, Matsuyama Y, Makuuchi M, Kojiro M, Ichida T, Arii S, Yamaoka Y. A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. *J Gastroenterol* 2006; **41**: 884-892 [PMID: 17048053 DOI: 10.1007/s00535-006-1878-y]

20 **Kitai S**, Kudo M, Minami Y, Ueshima K, Chung H, Hagiwara S, Inoue T, Ishikawa E, Takahashi S, Asakuma Y, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T. A new prognostic staging system for hepatocellular carcinoma: value of the biomarker combined Japan integrated staging score. *Intervirology* 2008; **51 Suppl 1**: 86-94 [PMID: 18544953 DOI: 10.1159/000122599]

21 **Hsu CY**, Huang YH, Hsia CY, Su CW, Lin HC, Loong CC, Chiou YY, Chiang JH, Lee PC, Huo TI, Lee SD. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. *J Hepatol* 2010; **53**: 108-117 [PMID: 20451283 DOI: 10.1016/j.jhep.2010.01.038]

22 **Yau T**, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. *Gastroenterology* 2014; **146**: 1691-700.e3 [PMID: 24583061 DOI: 10.1053/j.gastro.2014.02.032]

23 **Adhoute X**, Penaranda G, Bronowicki JP, Raoul JL. Usefulness of the HKLC vs. the BCLC staging system in a European HCC cohort. *J Hepatol* 2015; **62**: 492-493 [PMID: 25194894 DOI: 10.1016/j.jhep.2014.08.035]

24 [**European Association For The Study Of The Liver**](http://www.ncbi.nlm.nih.gov/pubmed/?term=European%20Association%20For%20The%20Study%20Of%20The%20Liver%5BCorporate%20Author%5D); [European Organisation For Research And Treatment Of Cancer](http://www.ncbi.nlm.nih.gov/pubmed/?term=European%20Organisation%20For%20Research%20And%20Treatment%20Of%20Cancer%5BCorporate%20Author%5D). EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* 2012; **56**: 908-943 [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001]

25 **Bolondi L**, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, Raoul JL, Sangro B. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. *Semin Liver Dis* 2012; **32**: 348-359 [PMID: 23397536 DOI: 10.1055/s-0032-1329906]

26 **Chang WT**, Kao WY, Chau GY, Su CW, Lei HJ, Wu JC, Hsia CY, Lui WY, King KL, Lee SD. Hepatic resection can provide long-term survival of patients with non-early-stage hepatocellular carcinoma: extending the indication for resection? *Surgery* 2012; **152**: 809-820 [PMID: 22766361 DOI: 10.1016/j.surg.2012.03.024]

27 **Torzilli G**, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, Vauthey JN, Choti MA, De Santibanes E, Donadon M, Morenghi E, Makuuchi M. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. *Ann Surg* 2013; **257**: 929-937 [PMID: 23426336 DOI: 10.1097/SLA.0b013e31828329b8]

28 **Vitale A**, Burra P, Frigo AC, Trevisani F, Farinati F, Spolverato G, Volk M, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Svegliati Baroni G, Virdone R, Cillo U. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. *J Hepatol* 2015; **62**: 617-624 [PMID: 25450706 DOI: 10.1016/j.jhep.2014.10.037]

29 **Xu L**, Peng ZW, Chen MS, Shi M, Zhang YJ, Guo RP, Lin XJ, Lau WY. Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. *J Hepatol* 2015; **63**: 122-130 [PMID: 25725438 DOI: 10.1016/j.jhep.2015.02.034]

30 **Xue TC**, Xie XY, Zhang L, Yin X, Zhang BH, Ren ZG. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. *BMC Gastroenterol* 2013; **13**: 60 [PMID: 23566041 DOI: 10.1186/1471-230X-13-60]

31 **Llovet JM**, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Brú C, Rodés J, Bruix J. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. *Hepatology* 1999; **29**: 62-67 [PMID: 9862851 DOI: 10.1002/hep.510290145]

32 **Huitzil-Melendez FD**, Capanu M, O'Reilly EM, Duffy A, Gansukh B, Saltz LL, Abou-Alfa GK. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? *J Clin Oncol* 2010; **28**: 2889-2895 [PMID: 20458042 DOI: 10.1200/JCO.2009.25.9895]

33 **Collette S**, Bonnetain F, Paoletti X, Doffoel M, Bouché O, Raoul JL, Rougier P, Masskouri F, Bedenne L, Barbare JC. Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. *Ann Oncol* 2008; **19**: 1117-1126 [PMID: 18303031 DOI: 10.1093/annonc/mdn030]

34 **Zhang JF**, Shu ZJ, Xie CY, Li Q, Jin XH, Gu W, Jiang FJ, Ling CQ. Prognosis of unresectable hepatocellular carcinoma: comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese cohort. *PLoS One* 2014; **9**: e88182 [PMID: 24609114 DOI: 10.1371/journal.pone.0088182]

35 **Zhao Y**, Wang WJ, Guan S, Li HL, Xu RC, Wu JB, Liu JS, Li HP, Bai W, Yin ZX, Fan DM, Zhang ZL, Han GH. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. *Ann Oncol* 2013; **24**: 1786-1792 [PMID: 23508822 DOI: 10.1093/annonc/mdt072]

36 **Yau T**, Yao TJ, Chan P, Ng K, Fan ST, Poon RT. A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials. *Cancer* 2008; **113**: 2742-2751 [PMID: 18853421 DOI: 10.1002/cncr.23878]

37 **Leung TW**, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, Lau JT, Yu SC, Johnson PJ. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. *Cancer* 2002; **94**: 1760-1769 [PMID: 11920539]

38 **Adhoute X**, Penaranda G, Naude S, Raoul JL, Perrier H, Bayle O, Monnet O, Beaurain P, Bazin C, Pol B, Folgoc GL, Castellani P, Bronowicki JP, Bourlière M. Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process. *J Hepatol* 2015; **62**: 855-862 [PMID: 25463541 DOI: 10.1016/j.jhep.2014.11.014]

39 **Su TH**, Liu CJ, Yang HC, Liu CH, Chen PJ, Chen DS. The NIACE score helps predict the survival of Asian hepatocellular carcinoma patients. *J Gastroenterol Hepatol* 2015; **30**: 23

40 **Rosenkrantz AB**, Lee L, Matza BW, Kim S. Infiltrative hepatocellular carcinoma: comparison of MRI sequences for lesion conspicuity. *Clin Radiol* 2012; **67**: e105-e111 [PMID: 23026725 DOI: 10.1016/j.crad.2012.08.019]

41 **Benvegnù L**, Noventa F, Bernardinello E, Pontisso P, Gatta A, Alberti A. Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. *Gut* 2001; **48**: 110-115 [PMID: 11115831]

42 **Bruix J**, Sherman M; [American Association for the Study of Liver Diseases](http://www.ncbi.nlm.nih.gov/pubmed/?term=American%20Association%20for%20the%20Study%20of%20Liver%20Diseases%5BCorporate%20Author%5D). Management of hepatocellular carcinoma: an update. *Hepatology* 2011; **53**: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]

43 **Ochiai T**, Sonoyama T, Ichikawa D, Fujiwara H, Okamoto K, Sakakura C, Ueda Y, Otsuji E, Itoi H, Hagiwara A, Yamagishi H. Poor prognostic factors of hepatectomy in patients with resectable small hepatocellular carcinoma and cirrhosis. *J Cancer Res Clin Oncol* 2004; **130**: 197-202 [PMID: 14770307 DOI: 10.1007/s00432-003-0533-8]

44 **Adhoute X**, Penaranda G, Raoul JL, Bourliere M. Hepatocellular carcinoma scoring and staging systems. Do we need new tools? *J Hepatol* 2016; Epub ahead of print [PMID: 26912407 DOI: 10.1016/j.jhep.2016.01.038]

45 **Adhoute X**, Penaranda G, Raoul JL, Bourliere M. "Staging of Hepatocellular Carcinoma: BCLC system, what else!" *Liver Int* 2016; Epub ahead of print [PMID: 26778275 DOI: 10.1111/liv.13066]

46 **Llovet JM**, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008; **359**: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]

47 **Cheng AL**, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2009; **10**: 25-34 [PMID: 19095497 DOI: 10.1016/S1470-2045(08)70285-7]

48 **Bruix J**, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. *J Hepatol* 2012; **57**: 821-829 [PMID: 22727733 DOI: 10.1016/j.jhep.2012.06.014]

49 **Lo CM**, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. *Hepatology* 2002; **35**: 1164-1171 [PMID: 11981766 DOI: 10.1053/jhep.2002.33156]

50 **Llovet JM**, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet* 2002; **359**: 1734-1739 [PMID: 12049862 DOI: 10.1016/S0140-6736(02)08649-X]

51 **Oliveri RS**, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. *Cochrane Database Syst Rev* 2011; **(3)**: CD004787 [PMID: 21412886 DOI: 10.1002/14651858.CD004787.pub2]

52 **Llovet JM**, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. *Hepatology* 2003; **37**: 429-442 [PMID: 12540794 DOI: 10.1053/jhep.2003.50047]

53 **Gillmore R**, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, Meyer T. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. *J Hepatol* 2011; **55**: 1309-1316 [PMID: 21703196 DOI: 10.1016/j.jhep.2011.03.007]

54 **Kim BK**, Kim KA, Park JY, Ahn SH, Chon CY, Han KH, Kim SU, Kim MJ. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. *Eur J Cancer* 2013; **49**: 826-834 [PMID: 22995582 DOI: 10.1016/j.ejca.2012.08.022]

55 **Raoul JL**, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, Lencioni R. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. *Cancer Treat Rev* 2011; **37**: 212-220 [PMID: 20724077 DOI: 10.1016/j.ctrv.2010.07.006]

56 **Bruix J**, Reig M, Rimola J, Forner A, Burrel M, Vilana R, Ayuso C. Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. *Hepatology* 2011; **54**: 2238-2244 [PMID: 21932394 DOI: 10.1002/hep.24670]

57 **Wang W**, Zhao Y, Bai W, Han G. Response assessment for HCC patients treated with repeated TACE: The optimal time-point is still an open issue. *J Hepatol* 2015; **63**: 1530-1531 [PMID: 26256436 DOI: 10.1016/j.jhep.2015.07.031]

58 **Kadalayil L**, Benini R, Pallan L, O'Beirne J, Marelli L, Yu D, Hackshaw A, Fox R, Johnson P, Burroughs AK, Palmer DH, Meyer T. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. *Ann Oncol* 2013; **24**: 2565-2570 [PMID: 23857958 DOI: 10.1093/annonc/mdt247]

59 **Hucke F**, Pinter M, Graziadei I, Bota S, Vogel W, Müller C, Heinzl H, Waneck F, Trauner M, Peck-Radosavljevic M, Sieghart W. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. *J Hepatol* 2014; **61**: 1287-1296 [PMID: 25016222 DOI: 10.1016/j.jhep.2014.07.002]

60 **Adhoute X**, Penaranda G, Raoul JL, Perrier H, Castellani P, Conroy G. Hepatocellular carcinoma, NIACE score: an aid to the decision-making process before the first transarterial chemoembolization. *J Gastroenterol Hepatol* 2015; **30**: 339-340

61 **Adhoute X**, Penaranda G, Castellani P, Perrier H, Bourliere M. Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system? *World J Hepatol* 2015; **7**: 521-531 [PMID: 25848475 DOI: 10.4254/wjh.v7.i3.521]

62 **Sieghart W**, Hucke F, Pinter M, Graziadei I, Vogel W, Müller C, Heinzl H, Trauner M, Peck-Radosavljevic M. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. *Hepatology* 2013; **57**: 2261-2273 [PMID: 23316013 DOI: 10.1002/hep.26256]

63 **Georgiades C**, Geschwind JF, Harrison N, Hines-Peralta A, Liapi E, Hong K, Wu Z, Kamel I, Frangakis C. Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? *Radiology* 2012; **265**: 115-123 [PMID: 22891361 DOI: 10.1148/radiol.12112264]

64 **Adhoute X**, Penaranda G, Castellani P, Perrier H, Naude S, Monnet M. Unresectable hepatocellular carcinoma (HCC) treated by chemoembolisazation. What prognostic score use: ART, HAP, ABCR? A comparative French multicenter study. *J Gastroenterol Hepatol* 2014; **29**: 178-179

65 **Yang H**, Bae SH, Lee S, Lee HL, Jang JW, Choi JYl. Korean validation and comparison of prognostic scores for transarterial chemoembolization: ART, ABCR, HAP and modified HAP. *Hepatology* 2015; **62**: 437A

66 **Liu PH**, Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Chiou YY, Lin HC, Huo TI. When to Perform Surgical Resection or Radiofrequency Ablation for Early Hepatocellular Carcinoma?: A Nomogram-guided Treatment Strategy. *Medicine (Baltimore)* 2015; **94**: e1808 [PMID: 26512576 DOI: 10.1097/MD.0000000000001808]

67 **Adhoute X**, Penaranda G, Raoul JL, Pol B, Bollon E, Perrier H. Hepatocellular carcinoma, NIACE score: A simple tool to better distinguish patients at risk of relapse after surgery. *J Gastroenterol Hepatol* 2015; **30**: 341

**P-Reviewer:** Cerwenka HR, Frenette C, Johnson PJ **S-Editor:** Gong ZM

**L-Editor:** **E-Editor:**



**Figure 1 Common parameters between hepatocellular carcinoma classifications and scores.** AFP: alpha-fetoprotein; CLIP: Cancer of the Liver Italian Program; BCLC: Barcelona Clinic Liver Cancer; JIS: Japan Integrated Staging; HKLC: Hong Kong Liver Cancer; TIS: Taipei Integrated Scoring System; ECOG (PS): Eastern Cooperative Oncology Group (Performance Status).



**Figure 2 Barcelona Clinic Liver Cancer system.**



**Figure 3 APASL guidelines on the treatment algorithm for hepatocellular carcinoma.** HCC: hepatocellular carcinoma; TACE: transarterial chemoembolization.



**Figure 4 Hong Kong Liver Cancer classification.** EVM: Extrahepatic vascular invasion/metastasis; BSC: best supportive care; TACE: transarterial chemoembolization; ECOG: Eastern Cooperative Oncology Group.

 **Figure 5 Evolution of the median overall survival according to the NIACE score in Barcelona Clinic Liver Cancer stage C patients from a French multicenter study, treated by Sorafenib (black bars center 2, grey bars center 3, white bars center 4)[38].** BCLC: Barcelona Clinic Liver Cancer.



**Figure 6 Evolution of the median overall survival according to the NIACE score in hepatocellular carcinoma patients from a French multicenter study treated by transarterial chemoembolization (grey bars center 1, black bars center 2)[60].** TACE: transarterial chemoembolization.



**Figure 7 Prognostic scores designed to transarterial chemoembolization, an aid to the decision making process: in practice.** BCLC: Barcelona Clinic Liver Cancer; HCC: hepatocellular carcinoma; TACE: transarterial chemoembolization; CT: Computed tomography; ART: Assessment for Retreatment with TACE; ECOG (PS), Eastern Cooperative Oncology Group (Performance Status).



**Figure 8 Nomogram for hepatocellular carcinoma recurrence after radiofrequency ablation[66].**



**Figure 9 Evolution of the median overall survival according to the NIACE score in hepatocellular carcinoma patients from a French multicenter study treated by surgery/radiofrequency ablation (grey bars center 5, black bars center 1)[67].**

**Table 1 Hepatocellular carcinoma scores and staging system recently published**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Scores and classifications** | **Liver function**  | **AFP** | **PS** | **Tumor spread**  |
| Okuda 1985  | Ascites, albumin,bilirubin | No | No | Hepatic spread50%< *vs* > 50% |
| CLIP 1998  | Child-Pugh score | < 400 *vs* ≥ 400 ng/mL | No | Nodule(s), Hepatic spread 50% ≤ *vs* > 50%, Portal vein thrombosis |
| GRETCH 1999 | Bilirubine, phosphatases alcalines | < 35 *vs* ≥ 35 ng/mL | Yes | Portal vein thrombosis |
| BCLC 1999 | Child-Pugh score | No | Yes | Nodule(s), size,Portal vein thrombosis |
| c-JIS 2003 | Child-Pugh score | No | No | TNM LCSGJ  |
| bm-JIS 2008 | Child-Pugh score | Yes (+ AFP-L3 + DCP) | No | TNM LCSGJ |
| TIS 2010 | Child-Pugh score | < 400 *vs* ≥ 400 ng/mL | No | Total tumor volume  |
| HKLC 2014  | Child-Pugh score | No | Yes |  Nodule(s), sizePortal vein thrombosis |

BCLC: Barcelona Clinic Liver Cancer; CLIP: Cancer of the Liver Italian Program; JIS: Japan Integrated Staging; HKLC: Hong Kong Liver Cancer; TIS: Taipei Integrated Scoring System; AFP: alpha-fetoprotein; PS: Performance Status.

**Table 2 Definitions of the Okuda score and the CLIP score**

|  |
| --- |
| **Okuda score** |
| **parameters** | **(+) 1 point** | **(-) 0 point** |
| Tumor spread  | > 50% | < 50% |
| Albumin, g/dl | < 3 | > 3 |
| Bilirubin, mg/dl | > 3 | < 3 |
| Ascites | yes | no |
| **CLIP score** |
| **parameters** | **Points** |
|  | 0 | 1 | 2 |
| Child-Pugh score  | A | B | C |
| Tumor spread  | Unidolar and hepatic spread ≤ 50% | Multinodular and hepatic spread ≤ 50% | Massive or hepatic spread > 50% |
| Portal vein thrombosis | no | yes |  |
| AFP, ng/dl | < 400 | ≥ 400 |  |

AFP: alpha-fetoprotein.

**Table 3 Definitions of the c-JIS score and the bm-JIS score**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **0 point** | **1 point** | **2 points** | **3 points** |
| score c-JIS |  |  |  |  |
| Child-Pugh stage | A | B | C |  |
| TNM stage by LCSGJ1 | I | II | III | IV |
| score bm-JIS |  |  |  |  |
| Child-Pugh stage | A | B | C |  |
| TNM stage by LCSGJ1 | I | II | III | IV |
| Elevated tumor markers, n (AFP, AFP-L3, DCP) | 0 | 1 | 2 or 3 |  |

1Definitions of the TNM stage by the LCSGJ; Stage I: T1 (fulfilling 3 T factors) N0 M0; Stage II: T2 (fulfilling 2 T factors) N0 M0; Stage III: T3 (fulfilling 1 T factor) N0 M0; Stage IV: T4 (fulfilling 0 T factor) N0 M0 or any T N0 – 1 M1; T factor: (1) single, (2) <2 cm, and (3) no vascular involvement. LCSGJ: Liver Cancer Study Group of Japan; JIS: Japan Integrated Staging.

**Table 4 Barcelona Clinic Liver Cancer C hepatocellular carcinoma, a broad spectrum of tumors; example of the Advanced Liver Cancer Prognostic System score[36]**

|  |  |
| --- | --- |
| **Parameters** | **Points** |
| Ascites | 2 |
| Abdominal pain | 2 |
| Weight loss | 2 |
| Child-Pugh grade A/B/C | 0/2/5 |
| alkaline phosphatase, UI/L > 200 | 3 |
| Bilirubin, mcmol/L ≤ 33/> 33-≤ 50/> 50  | 0/1/3 |
| Urea, mmol/L > 8.9 | 2 |
| Portal vein thrombosis | 3 |
| Tumor size: Diffuse/ > 5 cm/≤ 5 cm | 4/3/0 |
| Lung metastases | 3 |
| AFP, ng/mL > 400 | 4 |
| Probability of patients surviving at least 3 mo estimated by the ALCPS Score[36] |
| Score ≤ 8 points: 82.0% (95%CI: 76.5%-87.5%) |
| Score 9 -15 points: 53.4% (95% CI: 48.3%-57.7%) |
| Score ≥ 16 points: 18.9% (95%CI : 14.7%-23.3%) |

ALCPS: Advanced Liver Cancer Prognostic System.

**Table 5 NIACE score**

|  |  |
| --- | --- |
| **Score NIACE**  | **points** |
| Nodules < 3Nodules ≥ 3 | 01 |
| Infiltrative HCC: noInfiltrative HCC: yes | 01.5 |
| AFP < 200 ng/ml (at baseline) AFP ≥ 200 ng/ml (at baseline)  | 01.5 |
| Child-Pugh grade AChild-Pugh grade B | 01.5 |
| ECOG PS 0ECOG PS ≥ 1 | 01.5 |

AFP: alpha-fetoprotein; HCC: Hepatocellular carcinoma; ECOG (PS): Eastern Cooperative Oncology Group (Performance Status).

**Table 6 Comparison of prognostic performance of the NIACE, BCLC, HKLC, and CLIP systems[44]**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Score** | **Discriminatory ability****linear trend test** | **Homogeneity likelihood****ratio test** | **Akaike information criterion** | **C-index****[95%CI]** |
| **LT (*χ²*)** | ***P* value** | **LR (*χ²*)** | ***P* value** |
| NIACE | 91.6906 | < 0.0001 | 532.0369 | < 0.0001 | 10648.198 | 0.718[0.688-0.748] |
| BCLC | 79.0342 | < 0.0001 | 380.4100 | < 0.0001 | 10805.825 | 0.674[0.645-0.704] |
| HKLC | 71.8861 | < 0.0001 | 455.3169 | < 0.0001 | 10740.918 | 0.698[0.673-0.731] |
| CLIP | 87.2785 | < 0.0001 | 430.3872 | < 0.0001 | 10749.848 | 0.716[0.687-0.746] |

BCLC: Barcelona Clinic Liver Cancer; CLIP: Cancer of the Liver Italian Program; HKLC: Hong Kong Liver Cancer; LR: likelihood ratio; LT: *χ²* linear trend test.

**Table 7 Prognostic scores before the first transarterial chemoembolization**

|  |  |  |
| --- | --- | --- |
| **HAP (0 to 4 points)** | **NIACE (0 to 7 points)** | **STATE** |
| Before the first TACE |
| Albumin < 36 g/dl | 1 point | ≥ 3 nodules | 1 point | albumin (g/L)  |
| Bilirubin > 17 mcmol/l | 1 point | infiltrative HCC *vs* nodular HCC | 1.5 points |
| -12 (tumour load exceeding the up-to-7 criteria) |
| 0 |
| AFP > 400 ng/ml | 1 point | AFP ≥ 200 ng/ml | 1.5 points |
| Child-Pugh A *vs* Child-Pugh B | 0 |
| -12 (if CRP ≥ 1 mg/dl) |
| 1.5 points |
| 4- size of dominant tumour > 70 mm | 1 point | ECOG PS ≥ 1 | 1.5 points |
| No chemoembolization |
| ≥ 2 points | > 3 points | < 18 points |

HAP: Hepatoma arterial-embolisation prognostic; STATE: Selection for TrAnsarterial chemoembolisation TrEatment;

**Table 8 Pronostic scores before retreatment with transarterial chemoembolization**

|  |  |
| --- | --- |
| **ART (0 to 8 points)** | **ABCR (-3 to 6 points)** |
| Before the second, the third TACE….. |
| no radiological response | 1 point | AFP < 200 ng/mlAFP ≥ 200 ng/ml | 01 point |
| AST increased > 25% | 4 points | BCLC A/B/C | 0/2/3 points |
| Child-Pugh increased: 1 point | 1.5 points | Child-Pugh increased ≥ 2 points | 2 points |
| Increased: ≥ 2 points  | 3 points | radiological response | -3 points |
| No chemoembolization |
| ART ≥ 2.5 points | ABCR > 2 points |

TACE: transarterial chemoembolization; ART: Assessment for retreatment with TACE.